Life Sciences Tools & Services
Case studies in life sciences tools & services.
10x Genomics: Protect the Platform or Trade for Certainty?
On 28 February 2023, a federal court in Delaware issued a claim-construction order in a patent case brought by 10x Genomics and Prognosys Biosciences against NanoString Technologies. The order adopted plain-and-ordinary-meaning constructions for several disputed terms and rejected a number of additional limitations proposed by NanoString. Read case
Agilent Technologies: Integrating Biocare—How Fast, and Where?
Nearly three months after completing its acquisition of Biocare Medical, Agilent Technologies had a choice to make about how the two organizations would work together. The deal was closed, and Biocare had joined Agilent’s Life Sciences and Diagnostics Markets group. Read case
Bio-Techne: Funding the next phase of CGT growth
Bio-Techne had invested in specialized reagents and manufacturing capabilities for cell and gene therapies (CGT), while reporting weak organic growth in its largest segment. It also had a company-wide capital plan and a large future contractual purchase commitment tied to Wilson Wolf. Read case
Charles River Laboratories: Turning an AMAP Goal into a Portfolio
On 16 April 2024, Charles River Laboratories International announced its Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives that reduce reliance on animal testing in drug discovery and development. Read case
Danaher — Integrating Masimo Without Diluting Its Edge
Julie Sawyer Montgomery had become Danaher's President and CEO two days earlier. She had spent years in Diagnostics, first leading Beckman Coulter Diagnostics and later serving as the executive responsible for the Diagnostics platform. She had also led Danaher's acquisition of Masimo. Read case
Strategy Case: IQVIA — Connecting Data and Clinical Research
Suppose IQVIA’s corporate strategy team is asked to advise its executive leadership on the next planning cycle. Should the company keep decision-making and accountability mainly within its three business segments, coordinate selected customer opportunities across them, or prioritize a broader integrated platform model? Read case
Mettler-Toledo — Keeping Precision in Motion
On 8 February 2024, Mettler-Toledo reported that fourth-quarter sales had been affected by approximately $58 million of shipping delays “with a new external European logistics service provider.” Management expected the delayed sales to be largely recovered in the first quarter of 2024. Read case
Revvity: Where to Place the Next Three Years of Bets
In October 2026, Revvity’s hypothetical executive committee is setting priorities for the next three years. A definitive agreement to divest substantially all assets related to China Immunodiagnostics (China IDX) has been signed, but the transaction has not closed. Read case
Sotera Health: Where Should the Next Growth Dollar Go?
In May 2026, Sotera Health appointed Alton Shader chief executive, effective May 26, with former CEO Michael B. Petras, Jr. becoming executive chairman. The company’s second-quarter filing described a familiar corporate task: its chief executive also serves as chief operating decision maker and evaluates the company’s three businesses using segment revenue and segment income. Read case
Thermo Fisher and Olink — Scaling Proteomics Through Access or Integration?
On 17 October 2023, Thermo Fisher Scientific announced that both boards had approved its proposal to acquire Olink Holding for $26 per share or American depositary share in cash. The announcement valued the transaction at approximately $3.1 billion, including $143 million of Olink net cash, and represented a 74% premium to Olink’s closing share price the prior day. Read case
Waters Corporation — Funding the Next Adjacency
At its 19 May 2022 Analyst and Investor Day, Waters Corporation described a “Market+” strategy: execute in core markets and build exposure to adjacent markets. Management identified bio-separations, bioprocess characterization, LC-MS diagnostics, battery testing and sustainable polymers as potential opportunities. Read case
West Pharmaceutical Services — Capacity Before the Rebound?
West Pharmaceutical Services had maintained its 2023 capital-spending guidance at $350 million. That plan included incremental capacity expansions at existing high-value product (HVP) facilities. Through September, the company had spent $253.3 million on capital expenditures. Read case